ArticleBMC infectious diseases2025
Use of interferon-gamma release assay (IGRA) and CXCL-10/IP-10 for latent tuberculosis infection (LTBI) screening in chronic kidney disease and hemodialysis patients.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy ofFrontiers in immunology · 2026Pooled it
- Factors associated with interferon-gamma release assay positivity in patients with psoriasis: a cross-sectional study.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThere is increasing evidence that patients with chronic kidney disease (CKD) are at risk of acquiring latent tuberculosis infection (LTBI) or developing active tuberculosis (TB). However, the diagnosis of LTBI is still a challenge due to the limitations of current tests, which rely on the host’s cellular immune response against Mycobacterium tuberculosis (Mtb) – that may be compromised in this population. Herein, we assessed the prevalence of LTBI and its predictors among patients with CKD, including those undergoing routine hemodialysis (HD).
methodsA prospective cross-sectional study was conducted in a tertiary nephrology referral center in Rio de Janeiro, Brazil. LTBI was diagnosed using interferon-gamma release assay (IGRA; QuantiFERON-TB Gold Plus, QFT-Plus). CXCL-10/IP-10 release assay was measured in QFT-Plus supernatants.
resultsA total of 123 patients were enrolled, including 111 (90.2%) from the CKD group and 12 (9.8%) from the HD group. IGRA results positive in 39 (31.7%) overall: 36/111 (32.4%) in CKD group and 3/12 (25%) in HD group. Indeterminate IGRA results were found in 4/123 (3.3%) patients. Positive CXCL-10/IP-10 responses were observed in 49/123 (39.8%) patients. A significant agreement was observed between IGRA and CXCL-10/IP-10 results, with concordance in 69% of cases (p < o.05). Multivariate regression analysis identified that lack of BCG vaccination with (adjusted odds ratio [aOR] 7.4; 95% CI 2.15–25.48; p = 0.0014) and a positive CXCL-10/IP-10 result (aOR 4.48; 95% CI 1.87–10.76]; p = < 0.001) as independent risk factors for LTBI in both CKD and HD patients.
conclusionThe IGRA QFT-Plus was shown to be a useful method in the surveillance of LTBI in critical stages of CKD and routine hemodialysis. Mtb-specific CXCL-10/IP-10 responses were associated with a positive IGRA and could provide an useful adjuvant LTBI biomarker in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.